Van Herk Groep News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Van herk groep. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Van Herk Groep Today - Breaking & Trending Today
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital | More News pipelinereview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pipelinereview.com Daily Mail and Mail on Sunday newspapers.
A closer look at venture capital in the Netherlands pitchbook.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pitchbook.com Daily Mail and Mail on Sunday newspapers.
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs VANCOUVER, British Columbia and SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a transaction with Van Herk Investments, a leading European life science investor, to create and fund a new company called Sairopa, with a pipeline focused on research and development of non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform. Chinook will own approximately 40 percent of Sairopa after the first tranche of financing from Van Herk and have one seat on Sairopa’s Board of Directors. ....
Hits: 1900 - Seed investment by Swanbridge Capital and Van Herk Ventures with support from Health~Holland ROTTERDAM, The Netherlands I February 8, 2021 I Pan Cancer T B.V., a biotech spin-off from the Erasmus Medical Center founded by Prof. Dr. Reno Debets (CSO) and Dr. Dora Hammerl (VP R&D), announces the closing of a seed investment and start of operations. Together with Katrien Reynders-Frederix (CEO), the team is committed to the discovery and development of novel TCR therapies against solid tumors such as triple negative breast cancer, bladder cancer, lung cancer, and glioma. Seed investors are Swanbridge Capital and Van Herk Ventures, and the Company is further awarded a Health~Holland grant for a public-private-partnership with Erasmus Medical Center. ....